Sigma Labs, Inc. Files an Important Patent on New Manufacturing Technology for Dental Implants and Biomedical Prosthetics

Santa Fe, New Mexico – December 1, 2011

Sigma Labs, Inc. (OTCBB: SGLB) announced today that its collaborative work with a dental implant manufacturer has resulted in the filing of a potentially ground-breaking patent for a new manufacturing technology that appears to significantly improve integration between an implant and bone.

Richard Mah, CEO of Sigma Labs, states that “this may be a potential game-changer for dental implants and possibly for other prosthetics by reducing the healing time without the need for coatings or additives used by other manufacturers.”

An officer of OmegaTi Bio, Inc., a participating member of the research team, confirms that “dental implants made using his breakthrough manufacturing technology are integrating very well within a four week time period during preclinical trials.  There have been fewer indications of pain, or inflammation and minimal bone remodeling after implantation as compared to current dental implant technology.”

Mark Cola, President of Sigma Labs, states that “we are initiating additional trials for further evaluation as well as planning for successful product introduction and launch into the $4B worldwide implant market.”

Enhanced by Zemanta